Portola Pharmaceuticals clinical trials
Acquired by AstraZeneca, Jul 21, 2021 · source ↗
The registry lists 23 studies whose lead sponsor is Portola Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 22, 2023.
- 23studies on the registry
- 0open to participants now
Before and after it joined AstraZeneca
- First submitted before Portola Pharmaceuticals became part of AstraZeneca
- 23
- First submitted after Portola Pharmaceuticals became part of AstraZeneca
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Portola Pharmaceuticals’s studies test, most studies first; none is open now — 8 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 23 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 612
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 1 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- Portola Pharmaceuticals23 studies
Something wrong with this grouping? Tell us on the AstraZeneca page.
Studies
Recruiting first, then most recently updated. Showing 23 of 23. All AstraZeneca studies →
- A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal ImpairmentCompletedNCT00999336Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCICompletedNCT00751231Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban DosingTerminatedNCT03330457Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male VolunteersCompletedNCT01765868Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaCompletedNCT03083704Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of ApixabanCompletedNCT02207725Phase 3
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban FormulationsCompletedNCT02596100Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)CompletedNCT01583218Phase 3
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to WarfarinCompletedNCT00742859Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)CompletedNCT01758432Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)CompletedNCT00375609Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial FlutterCompletedNCT01229254Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor AntidoteCompletedNCT03218241Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal ImpairmentTerminatedNCT00984113Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male SubjectsCompletedNCT01765855Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian SubjectsCompletedNCT03310021Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)CompletedNCT03551730Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)CompletedNCT03578146Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding OutcomesWithdrawnNCT03613402
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)CompletedNCT03551743Phase 2
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa AntagonistCompletedNCT03397888Phase 1
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca
- A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of RivaroxabanCompletedNCT02220725Phase 3
Sponsor listed in the registry: Portola Pharmaceuticals · First submitted before Portola Pharmaceuticals became part of AstraZeneca